Brief: Aerovate Therapeutics Announces First Quarter 2022 Financial Results
16/05/2022 13:19
May 16 (Reuters) - Aerovate Therapeutics Inc AVTE.O :
* AEROVATE THERAPEUTICS ANNOUNCES FIRST QUARTER 2022
FINANCIAL
RESULTS
* REITERATING STRONG FINANCIAL POSITION FUNDING OPERATIONS
INTO
SECOND HALF OF 2025
* UPDATING GUIDANCE AND EXPECT TO REPORT TOPLINE DATA FROM
PHASE
2B PORTION OF IMPAHCT TRIAL IN Q4 OF 2023 OR Q1 OF 2024
* QTRLY NET LOSS PER SHARE $0.45
Source text for Eikon: ID:nGNX22067M
Further company coverage: AVTE.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Jade Biosciences
See all newsBrief: Jade Biosciences Announces Preclinical Data Characterizing Jade301, A Potentially Best-In-Class, Half-Life-Extended Anti-Ifn-Β Monoclonal Antibody In Development For Dermatomyositis, At Eadv 2026
U.S. RESEARCH ROUNDUP-Cardinal Health, Lumentum Holdings, Public Storage
Jade Biosciences Inc reports results for the quarter ended June 30 - Earnings Summary
Jade Biosciences Q2 net loss widens as costs rise
Brief: Jade Biosciences, Inc Q2 Cash & Investments USD 461.2 Million